Supergravity and M-Theory

Supergravity provides the effective field theories for string compactifications. The deformation of the maximal supergravities by non-abelian gauge interactions is only possible for a restricted class of charges. Generically these `gaugings' involve a hierarchy of p-form fields which belong to specific representations of the duality group. The group-theoretical structure of this p-form hierarchy exhibits many interesting features. In the case of maximal supergravity the class of allowed deformations has intriguing connections with M/string theory.Comment: 28 pages, LaTeX fil

How Parents’ Ideals are Offset by Uncertainty and Fears : A Systematic Review of the Experiences of European Parents regarding the Sexual Education of Their Children

Funding Information: This study is part of a project funded by Fonds Wetenschappelijk Onderzoek Seksualiteit under grant 19.006. The authors thank Kristin Jansen, Oka Storms, Hannan Nhass, Simon Timmerman, Nelleke Westerveld, Wilma Schakenraad and Shirin Eftekharijam from Movisie, the Dutch National Centre of Expertise of Social Issues. Publisher Copyright: © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.Peer reviewedPublisher PD

New supersymmetric higher-derivative couplings: Full N=2 superspace does not count!

An extended class of N=2 locally supersymmetric invariants with higher-derivative couplings based on full superspace integrals, is constructed. These invariants may depend on unrestricted chiral supermultiplets, on vector supermultiplets and on the Weyl supermultiplet. Supersymmetry is realized off-shell. A non-renormalization theorem is proven according to which none of these invariants can contribute to the entropy and electric charges of BPS black holes. Some of these invariants may be relevant for topological string deformations.Comment: 24 pages, v2: version published in JHEP, one reference added and typos corrected, v3: reference adde

Electric and magnetic charges in N=2 conformal supergravity theories

General Lagrangians are constructed for N=2 conformal supergravity theories in four space-time dimensions involving gauge groups with abelian and/or non-abelian electric and magnetic charges. The charges are encoded in the gauge group embedding tensor. The scalar potential induced by the gauge interactions is quadratic in this tensor, and, when the embedding tensor is treated as a spurionic quantity, it is formally covariant with respect to electric/magnetic duality. This work establishes a general framework for studying any deformation induced by gauge interactions of matter-coupled N=2 supergravity theories. As an application, full and residual supersymmetry realizations in maximally symmetric space-times are reviewed. Furthermore, a general classification is presented of supersymmetric solutions in $\mathrm{AdS}_2\times S^2$ space-times. As it turns out, these solutions allow either eight or four supersymmetries. With four supersymmetries, the spinorial parameters are Killing spinors of $\mathrm{AdS}_2$ that are constant on $S^2$, so that they carry no spin, while the bosonic background is rotationally invariant.Comment: 49 pages, typos correcte

The Importance of Social Engagement in the Development of an HIV Cure : A Systematic Review of Stakeholder Perspectives

Funding Information: This research has been funded by Aidsfonds under Grant P-53001. Publisher Copyright: © 2023, The Author(s).Peer reviewedPublisher PD

Beyond community engagement : perspectives on the meaningful involvement of people with HIV and affected communities (MIPA) in HIV cure research in The Netherlands

First, we express our heartfelt gratitude to all the participants who generously shared their experiences and insights, making this research possible. Your contributions are invaluable and we sincerely thank you for your time and openness. Special appreciation goes to the Dutch HIV Association of People with HIV and the HIV consultants for their collaboration and support in participant recruitment. We further thank Lissa Agema and Vaneza Paulo for their dedication to the detailed transcriptions. The PAB and CAB deserve profound acknowledgment for their efforts and significant contributions in the development and conducting of this research. Last, we acknowledge the use of the large-language model ChatGPT and Grammarly for improving clarity and conciseness.Peer reviewe

Seroprevalence of HIV, hepatitis b, and hepatitis c among opioid drug users on methadone treatment in the netherlands

Background: Injecting drug users (IDU) remain an important population at risk for blood-borne infections such as human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV). In the Netherlands, a program is being implemented to offer annual voluntary screening for these infections to opioid drug users (ODUs) screened in methadone care. At two care sites where the program is now operating, our study aimed to estimate the seroprevalence among ODUs screened for HIV, HBV and HCV; to evaluate HBV vaccination coverage; and to assess the feasibility of monitoring seroprevalence trends by using routine annual screening data.Methods: Opioid drug users on methadone treatment are routinely offered voluntary screening for infectious diseases such as HIV, HBV and HCV. Data on uptake and outcome of anti-HIV, anti-HBc, and anti-HCV screening among ODUs receiving methadone were obtained from two regions: Amsterdam from 2004 to 2008 and Heerlen from 2003 to 2009.Findings: Annual screening uptake for HIV, HBV and HCV varied from 34 to 69%, depending on disease and screening site. Of users screened, 2.5% were HIV-positive in Amsterdam and 11% in Heerlen; 26% were HCV-positive in Amsterdam and 61% in Heerlen. Of those screened for HBV, evidence of current or previous infection (anti-HBc) was found among 33% in Amsterdam and 48% in Heerlen. In Amsterdam, 92% were fully vaccinated for HBV versus 45% in Heerlen.Conclusion: Annual screening for infectious diseases in all ODUs in methadone care is not fully implemented in the Netherlands. On average, more than half of the ODUs in methadone care in Heerlen and Amsterdam were screened for HIV, HBV and HCV. In addition, screening data indicate that HBV vaccination uptake was rather high. While the HIV prevalence among these ODUs was relatively low compared to other drug-using populations, the high HCV prevalence among this group underscores the need to expand annual screening and interventions to monitor HIV, HBV and HCV in the opioid drug-using population

Temperature effects on DNA damage during hibernation

During multiday torpor, deep-hibernating mammals maintain a hypometabolic state where heart rate and ventilation are reduced to 2%–4% of euthermic rates. It is hypothesized that this ischemia-like condition may cause DNA damage through reactive oxygen species production. The reason for intermittent rewarming (arousal) during hibernation might be to repair the accumulated DNA dam-age. Because increasing ambient temperatures (Ta’s) shortens torpor bout duration, we hypothesize that hibernating at higher Ta’swill result in a faster accumulation of genomic DNA damage. To test this, we kept 39 male and female garden dormice at a Ta of either 57C or 107C and obtained tissue at 1, 4, and 8 d in torpor to assess DNA damage and recruitment of DNA repair markers in splenocytes. DNA damage in splenocytes measured by comet assay was significantly higher in almost all torpor groups than in sum-mer euthermic groups. Damage accumulates in the first days of torpor at Ta = 57C (between days 1 and 4) but not at Ta = 107C. At the higher Ta, DNA damage is high at 24 h in torpor, indicating either a faster buildup of DNA damage at higher Ta’soranin-complete repair during arousals in dormice. At 57C, recruitment of the DNA repair protein 53BP1 paralleled the increase in DNA damage over time during torpor. In contrast, after 1 d in torpor at 107C, DNA damage levels were high, but 53BP1 was not re-cruited to the nuclear DNA yet. The data suggest a potential mis-match in the DNA damage/repair dynamics during torpor at higher Ta’s.</p

Validity and reliability of a medical record review method identifying transitional patient safety incidents in merged primary and secondary care patients' records.

OBJECTIVE: Inadequate information transfer during transitions in healthcare is a major patient safety issue. Aim of this study was to pilot a review of medical records to identify transitional safety incidents (TSIs) for use in a large intervention study and assess its reliability and validity. DESIGN: A retrospective medical record review study. SETTINGS AND PARTICIPANTS: Combined primary and secondary care medical records of 301 patients who had visited their general practitioner and the University Medical Center Utrecht, the Netherlands, in 2013 were randomly selected. Six trained reviewers assessed these medical records for presence of TSIs. OUTCOMES: To assess inter-rater reliability, 10% of medical records were independently reviewed twice. To assess validity, the identified TSIs were compared with a reference standard of three objectively identifiable TSIs. RESULTS: The reviewers identified TSIs in 52 (17.3%) of all transitional medical records. Variation between reviewers was high (range: 3-28 per 50 medical records). Positive agreement for finding a TSI between reviewers was 0%, negative agreement 80% and the Cohen's kappa -0.15. The reviewers identified 43 (22%) of 194 objectively identifiable TSIs. CONCLUSION: The reliability of our measurement tool for identifying TSIs in transitional medical record performed by clinicians was low. Although the TSIs that were identified by clinicians were valid, they missed 80% of them. Restructuring the record review procedure is necessary.This work was supported by the Dutch Ministry of Health, Welfare and Sports (VWS; grant number 320698), and Achmea Healthcare (grant number Z415)

The Development of Practice Recommendations for Drug-Disease Interactions by Literature Review and Expert Opinion

Background Drug-disease interactions negatively affect the benefit/risk ratio of drugs for specific populations. In these conditions drugs should be avoided, adjusted, or accompanied by extra monitoring. The motivation for many drug-disease interactions in the Summary of Product Characteristics (SmPC) is sometimes insufficiently supported by (accessible) evidence. As a consequence the translation of SmPC to clinical practice may lead to non-specific recommendations. For the translation of this information to the real world, it is necessary to evaluate the available knowledge about drug-disease interactions, and to formulate specific recommendations for prescribers and pharmacists. The aim of this paper is to describe a standardized method how to develop practice recommendations for drug-disease interactions by literature review and expert opinion. Methods The development of recommendations for drug-disease interactions will follow a six-step plan involving a multidisciplinary expert panel (1). The scope of the drug-disease interaction will be specified by defining the disease and by describing relevant effects of this drug-disease interaction. Drugs possibly involved in this drug-disease interaction are selected by checking the official product information, literature, and expert opinion (2). Evidence will be collected from the official product information, guidelines, handbooks, and primary literature (3). Study characteristics and outcomes will be evaluated and presented in standardized reports, including preliminary conclusions on the clinical relevance and practice recommendations (4). The multidisciplinary expert panel will discuss the reports and will either adopt or adjust the conclusions (5). Practice recommendations will be integrated in clinical decision support systems and published (6). The results of the evaluated drug-disease interactions will remain up-to-date by screening new risk information, periodic literature review, and (re)assessments initiated by health care providers. Actionable Recommendations The practice recommendations will result in advices for specific DDSI. The content and considerations of these DDSIs will be published and implemented in all Clinical Decision Support Systems in the Netherlands. Discussion The recommendations result in professional guidance in the context of individual patient care. The professional will be supported in the decision making in concerning pharmacotherapy for the treatment of a medical problem, and the clinical risks of the proposed medication in combination with specific diseases